Anti-TRAIL antibody (ab9959)
Key features and details
- Rabbit polyclonal to TRAIL
- Suitable for: Sandwich ELISA
- Isotype: IgG
Overview
-
Product name
Anti-TRAIL antibody
See all TRAIL primary antibodies -
Description
Rabbit polyclonal to TRAIL -
Host species
Rabbit -
Tested applications
Suitable for: Sandwich ELISAmore details -
Immunogen
Recombinant fragment corresponding to Human TRAIL aa 100 to the C-terminus. Highly pure (>98%). E.coli derived
Database link: P50591 -
General notes
Although some customers have been successful in IHC we no longer batch test in this application.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Lyophilized:Reconstitute with 200µl of sterile water. -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. -
Concentration information loading... -
Purity
Immunogen affinity purified -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Positive Controls
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab9959 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| Sandwich ELISA |
Use a concentration of 0.1 µg/ml.
To detect TRAIL by sandwich ELISA (using 100 μl/well antibody solution) a concentration of 0.5 - 2.0 μg/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with ab12124 as a detection antibody, allows the detection of at least 0.2 - 0.4 ng/well of recombinant TRAIL. |
| Notes |
|---|
|
Sandwich ELISA
Use a concentration of 0.1 µg/ml. To detect TRAIL by sandwich ELISA (using 100 μl/well antibody solution) a concentration of 0.5 - 2.0 μg/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with ab12124 as a detection antibody, allows the detection of at least 0.2 - 0.4 ng/well of recombinant TRAIL. |
Target
-
Function
Cytokine that binds to TNFRSF10A/TRAILR1, TNFRSF10B/TRAILR2, TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and possibly also to TNFRSF11B/OPG. Induces apoptosis. Its activity may be modulated by binding to the decoy receptors TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and TNFRSF11B/OPG that cannot induce apoptosis. -
Tissue specificity
Widespread; most predominant in spleen, lung and prostate. -
Sequence similarities
Belongs to the tumor necrosis factor family. -
Cellular localization
Membrane. - Information by UniProt
-
Alternative names
- Apo 2 ligand antibody
- APO 2L antibody
- Apo-2 ligand antibody
see all
Images
Datasheets and documents
-
Datasheet download
References (10)
ab9959 has been referenced in 10 publications.
- Chen J et al. Reprogramming immunosuppressive myeloid cells by activated T cells promotes the response to anti-PD-1 therapy in colorectal cancer. Signal Transduct Target Ther 6:4 (2021). PubMed: 33414378
- Kitamura Y et al. Anti-EGFR VHH-armed death receptor ligand-engineered allogeneic stem cells have therapeutic efficacy in diverse brain metastatic breast cancers. Sci Adv 7:N/A (2021). PubMed: 33658202
- Liu Z et al. Secreted TRAIL gene-modified adipose-derived stem cells exhibited potent tumor-suppressive effect in hepatocellular carcinoma cells. Immun Inflamm Dis 9:144-156 (2021). PubMed: 33156578
- Wang Y et al. NCTR25 fusion facilitates the formation of TRAIL polymers that selectively activate TRAIL receptors with higher potency and efficacy than TRAIL. Cancer Chemother Pharmacol 88:289-306 (2021). PubMed: 33942150
- Kong H et al. Biosilicified oncolytic adenovirus for cancer viral gene therapy. Biomater Sci 8:5317-5328 (2020). PubMed: 32779647
- Yoo JD et al. Designed ferritin nanocages displaying trimeric TRAIL and tumor-targeting peptides confer superior anti-tumor efficacy. Sci Rep 10:19997 (2020). PubMed: 33203916
- Lee GT et al. Dihydrotestosterone Increases Cytotoxic Activity of Macrophages on Prostate Cancer Cells via TRAIL. Endocrinology 160:2049-2060 (2019). PubMed: 31184711
- Li Q et al. Chemically modified liposomes carrying TRAIL target activated hepatic stellate cells and ameliorate hepatic fibrosis in vitro and in vivo. J Cell Mol Med N/A:N/A (2018). PubMed: 30592139
- He X et al. An Lnc RNA (GAS5)/SnoRNA-derived piRNA induces activation of TRAIL gene by site-specifically recruiting MLL/COMPASS-like complexes. Nucleic Acids Res 43:3712-25 (2015). IHC-P . PubMed: 25779046
- Graves JD et al. Apo2L/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity. Cancer Cell 26:177-89 (2014). WB ; Human . PubMed: 25043603
